Country Club Bank Buys 56,085 Shares of Kenvue Inc. $KVUE

Country Club Bank boosted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 22.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 303,211 shares of the company’s stock after purchasing an additional 56,085 shares during the period. Country Club Bank’s holdings in Kenvue were worth $4,954,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in KVUE. Evergreen Wealth Solutions LLC raised its stake in Kenvue by 2.6% during the 1st quarter. Evergreen Wealth Solutions LLC now owns 16,769 shares of the company’s stock valued at $402,000 after buying an additional 432 shares during the last quarter. AlphaCore Capital LLC grew its holdings in shares of Kenvue by 9.9% in the second quarter. AlphaCore Capital LLC now owns 5,287 shares of the company’s stock worth $111,000 after acquiring an additional 476 shares during the period. Empirical Finance LLC increased its position in Kenvue by 1.8% during the second quarter. Empirical Finance LLC now owns 28,309 shares of the company’s stock valued at $593,000 after acquiring an additional 491 shares during the last quarter. Proffitt & Goodson Inc. lifted its holdings in Kenvue by 8.2% in the second quarter. Proffitt & Goodson Inc. now owns 6,831 shares of the company’s stock valued at $143,000 after acquiring an additional 517 shares during the period. Finally, UMB Bank n.a. lifted its holdings in Kenvue by 22.3% in the second quarter. UMB Bank n.a. now owns 2,853 shares of the company’s stock valued at $60,000 after acquiring an additional 521 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

KVUE opened at $17.30 on Thursday. The firm has a market cap of $33.13 billion, a P/E ratio of 23.06 and a beta of 0.60. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $25.17. The company has a 50 day simple moving average of $16.28 and a two-hundred day simple moving average of $18.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The firm had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.83 billion. During the same period last year, the firm earned $0.28 EPS. The company’s revenue was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were issued a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. Kenvue’s dividend payout ratio (DPR) is currently 110.67%.

Insider Activity at Kenvue

In other Kenvue news, Director Jeffrey C. Smith acquired 3,200,000 shares of the company’s stock in a transaction dated Friday, December 12th. The stock was purchased at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the purchase, the director directly owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. The trade was a 13.27% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.68% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

KVUE has been the subject of a number of recent research reports. Johnson Rice restated a “neutral” rating on shares of Kenvue in a research note on Tuesday, October 28th. JPMorgan Chase & Co. cut their target price on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. Edward Jones downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. The Goldman Sachs Group dropped their price target on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a research note on Thursday, October 2nd. Finally, Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $20.23.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.